- Home
- NCI vs GOVX Comparison
NCI vs GOVX Comparison
Compare NCI & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- GOVX
- Stock Information
- Founded
- NCI 1992
- GOVX 2001
- Country
- NCI Hong Kong
- GOVX United States
- Employees
- NCI N/A
- GOVX N/A
- Industry
- NCI
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- GOVX Health Care
- Exchange
- NCI NYSE
- GOVX Nasdaq
- Market Cap
- NCI 7.4M
- GOVX 7.6M
- IPO Year
- NCI 2024
- GOVX N/A
- Fundamental
- Price
- NCI $2.06
- GOVX $0.69
- Analyst Decision
- NCI
- GOVX Strong Buy
- Analyst Count
- NCI 0
- GOVX 5
- Target Price
- NCI N/A
- GOVX $12.40
- AVG Volume (30 Days)
- NCI 173.5K
- GOVX 3.3M
- Earning Date
- NCI 07-22-2025
- GOVX 08-05-2025
- Dividend Yield
- NCI N/A
- GOVX N/A
- EPS Growth
- NCI 67.70
- GOVX N/A
- EPS
- NCI 0.26
- GOVX N/A
- Revenue
- NCI $30,340,230.00
- GOVX $5,591,576.00
- Revenue This Year
- NCI N/A
- GOVX N/A
- Revenue Next Year
- NCI N/A
- GOVX N/A
- P/E Ratio
- NCI $7.74
- GOVX N/A
- Revenue Growth
- NCI 35.28
- GOVX N/A
- 52 Week Low
- NCI $1.40
- GOVX $0.43
- 52 Week High
- NCI $9.00
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- GOVX 42.24
- Support Level
- NCI N/A
- GOVX $0.60
- Resistance Level
- NCI N/A
- GOVX $0.70
- Average True Range (ATR)
- NCI 0.00
- GOVX 0.08
- MACD
- NCI 0.00
- GOVX -0.00
- Stochastic Oscillator
- NCI 0.00
- GOVX 46.38
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company that is a one-stop apparel solution services provider. The company offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European and North American markets.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.